Full Press Release Details
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD).
CRVO
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Key Takeaway: CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Price reaction · baseline $14.47 (2024-09-25 close) · hit after-hours · clean, no other CRVO news in the window
day 0 close · peak
+5.8%
day 1
+4.6%
day 3
-0.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
6.8%
average across 6 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
Neflamapimod
Phase 2 · Moderate to Severe Acute Ischaemic Stroke